Skip to main content

Michael Didocha Joins Telix as Chief Financial Officer, Americas

MELBOURNE, Australia and INDIANAPOLIS, Aug. 31, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that Michael Didocha has joined the Company as Chief Financial Officer for the Americas region.

Michael joins with approximately 20 years’ experience in life science manufacturing and commercialisation. Prior to joining Telix, Michael worked at Roche where he served for 16 years across various executive positions, including as Director of Finance from 2017.

Mr. Didocha holds a Master of Business Administration in Finance and Accounting from Indiana University Kelley School of Business, and a Bachelor of Science in Mechanical Engineering from Georgia Institute of Technology.

On joining Telix, Michael stated, “Any cancer diagnosis today means that a patient is facing painful procedures and uncertain outcomes. The promise of personalised radionuclide therapies to treat cancer presents an exciting possibility to make a real difference in people’s lives. It is clear that Telix has both the talent and mindset to make these treatments a reality. It’s truly an honor to be joining this team, and I am very excited to be a part of this journey.”

Dr. Bernard Lambert, President, Telix Americas added, “With broad experience in strategic business planning and financial accounting across life sciences and medical devices, Michael is a strong fit to lead our financial operations in the Americas region. He joins at a pivotal moment in the Company’s evolution, as we prepare for the launch of illuccix®, with the hope that brings for US men suffering with prostate cancer.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s lead investigational product, illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,1 and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).2 Telix is also progressing marketing authorisation applications for illuccix® in the European Union3 and Canada.4 None of Telix’s products have received a marketing authorisation in any jurisdiction.

Telix Media Contact

Dr. Stewart Holmstrom
Telix Pharmaceuticals Limited
Director Corporate Communications
Email: stewart.holmstrom@telixpharma.com 

_______________________________
1
ASX disclosure 24/11/20.
2 ASX disclosure 14/04/21.
3 ASX disclosure 1/05/20.
4 ASX disclosure 16/12/20.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.